Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Biosimilar vs Herceptin in Healthy Male Volunteers
NCT05765357Phase 1Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jul 2017
- Primary completion
- Oct 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of trastuzumab in breast cancer and gastric cancer (GC) (2 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoint: Area under drug concentration - time curve (AUC0-t) at 56 days. Started Jul 2017; status: completed.
02
Drugs
03
Conditions
breast cancergastric cancer (GC)
Beyond the preview
Go deeper on NCT05765357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05765357.